On June 26, 2025, Aimed Alliance submitted a comment to the Centers for Medicare & Medicaid Services (CMS) on its draft guidance for the Medicare Drug Price Negotiation Program, 2026-2028. Aimed Alliance’s comment urged the agency to strengthen its approach to patient engagement by implementing a clear and continuous consumer engagement process, ensuring CMS is transparent regarding how it weighs and considers patient input in decision-making, and tracking and reporting on the impact of negotiations on consumer prescription drug costs and access. Read the comment here.
Last Updated on June 28, 2025 by Aimed Alliance
